30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Cellular Biomedicine's ReJoin for Knee OA Accepted for Trial in China -

Cellular Biomedicine's drug application for ReJoin® therapy for knee osteoarthritis was accepted for a Phase II clinical trial in China. ReJoin is an off-the-shelf autologous mesenchymal progenitor cell therapy, developed completely in-house. It comprises adipose tissue obtained from the patient that is expanded using a serum- and antibiotics-free culture medium, which is then formulated for ReJoin. This marks the company's second clinical trial accepted in China for stem cells this year, following a trial of AlloJoin® allogenic therapy for the same application. That trial launched earlier this month. (Cellular Biomedicine Group, 9/27/19)